Evidence map›Paper›PMID 30115913›Full record

ArticleTranslational psychiatry2018

Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model.

Jubao Duan, Harald H H Göring, Alan R Sanders, Winton Moy, Jessica Freda, Eugene I Drigalenko, Mark Kos, Deli He, Pablo V Gejman, MGS

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 2 countries.

Jubao DuanCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA. jduan@northshore.org.
Harald H H GöringSouth Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, San Antonio, TX, USA.
Alan R SandersCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Winton MoyCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Jessica FredaCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Eugene I DrigalenkoDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA.
Mark KosSouth Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, San Antonio, TX, USA.
Deli HeCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Pablo V GejmanCenter for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA. pgejman@northshore.org.
MGS
NorthShore University HealthSystem · USNational Cancer Institute · USThe University of Queensland · AUThe University of Texas Rio Grande Valley · USUniversity of California, San Francisco · USUniversity of Iowa · USWashington University in St. Louis · USEmory University · USTexas Biomedical Research Institute · USUniversity of Colorado Denver · US

Funding

MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059571 · NIMH · UNIVERSITY OF CHICAGO · PI GEJMAN, PABLO V. · 1999 to 2007
$8.0M
Systematic Functional Interpretation of Regulatory Variants in SchizophreniaR01MH106575 · NIMH · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI DUAN, JUBAO · 2016 to 2025
$6.1M
A Genome-Wide Association Study of SchizophreniaU01MH079469 · NIMH · NORTHSHORE UNIVERSITY HEALTHSYSTEM · PI GEJMAN, PABLO V. · 2007 to 2009
$4.4M
Construction of a Biomedical Research Facility at the U*C06RR020547 · NCRR · UNIV/TEXAS BROWNSVILLE & SOUTHMOST COLL · PI KROUSE, JOHN H · 2010 to 2010
$4.0M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH060879 · NIMH · WASHINGTON UNIVERSITY · PI CLONINGER, C. ROBERT · 1999 to 2006
$2.7M
1/2 An Integrative Genetic Investigation of SchizophreniaR01MH094091 · NIMH · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI GEJMAN, PABLO V. · 2011 to 2015
$2.7M
Joint Mapping of Genome-Wide Gene Expression and Association in a Schizophrenia DRC2MH090030 · NIMH · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI SANDERS, ALAN R · 2009 to 2010
$2.0M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059586 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SILVERMAN, JEREMY M. · 1999 to 2006
$1.9M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH061675 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI LEVINSON, DOUGLAS FREDERICK · 1999 to 2007
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059587 · NIMH · EMORY UNIVERSITY · PI AMIN, FAROOQ · 1999 to 2006
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059565 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 1999 to 2006
$1.7M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059588 · NIMH · UNIVERSITY OF QUEENSLAND · PI MOWRY, BRYAN JOHN · 1999 to 2006
$1.4M
NCRR NIH HHS C06 RR020547NIDA NIH HHS R21 DA041600NIMH NIH HHS R01 MH059565NIMH NIH HHS R01 MH059566NIMH NIH HHS R01 MH059571NIMH NIH HHS R01 MH059586NIMH NIH HHS R01 MH059587NIMH NIH HHS R01 MH059588NIMH NIH HHS R01 MH060870NIMH NIH HHS R01 MH060879NIMH NIH HHS R01 MH061675NIMH NIH HHS R01 MH067257NIMH NIH HHS R01 MH081800NIMH NIH HHS R01 MH094091NIMH NIH HHS R01 MH094116NIMH NIH HHS R01 MH106575NIMH NIH HHS RC2 MH090030NIMH NIH HHS U01 MH046276NIMH NIH HHS U01 MH079469NIMH NIH HHS U01 MH079470
6 · The paper itself

Abstract

The dopaminergic hypothesis of schizophrenia (SZ) postulates that dopaminergic over activity causes psychosis, a central feature of SZ, based on the observation that blocking dopamine (DA) improves psychotic symptoms. DA is known to have both receptor- and non-receptor-mediated effects, including oxidative mechanisms that lead to apoptosis. The role of DA-mediated oxidative processes in SZ has been little studied. Here, we have used a cell perturbation approach and measured transcriptomic profiles by RNAseq to study the effect of DA exposure on transcription in B-cell transformed lymphoblastoid cell lines (LCLs) from 514 SZ cases and 690 controls. We found that DA had widespread effects on both cell growth and gene expression in LCLs. Overall, 1455 genes showed statistically significant differential DA response in SZ cases and controls. This set of differentially expressed genes is enriched for brain expression and for functions related to immune processes and apoptosis, suggesting that DA may play a role in SZ pathogenesis through modulating those systems. Moreover, we observed a non-significant enrichment of genes near genome-wide significant SZ loci and with genes spanned by SZ-associated copy number variants (CNVs), which suggests convergent pathogenic mechanisms detected by both genetic association and gene expression. The study suggests a novel role of DA in the biological processes of immune and apoptosis that may be relevant to SZ pathogenesis. Furthermore, our results show the utility of pathophysiologically relevant perturbation experiments to investigate the biology of complex mental disorders.

Indexed as

TranscriptomeApoptosisBrainCase-Control StudiesCell LineCell ProliferationDNA Copy Number VariationsDopamine AntagonistsFemaleHumansMaleSchizophreniaSequence Analysis, RNADopamine Antagonists

Identifiers

PMID30115913
PMCPMC6095865
OpenAlexW2887083668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.